Drug Trial Radar · NCT05280028
HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
Last checked: Nov 20, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 7, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Far Eastern Memorial HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 15, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Therefore, the aim of this study is to assess the therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability, arterial stiffness, atherosclerosis, sleep, and depression between tibolone and E2V/MPA. From the results, the investigators will compare the effect of tibolone versus E2V/MPA on overactive bladder symptoms, sexual function, autonomic function, arterial stiffness, atherosclerosis, sleep and depression.
Conditions
- Menopausal Syndrome
Interventions
Tibolone 2.5 mgDrug
Tibolone 2.5 mg per day
Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mgDrug
Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overactive bladder symptomsTime frame: 3 months
- Sexual function indexTime frame: 3 months
- Autonomic functionTime frame: 3 months
- Arterial stiffnessTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.